The latest new contracts, like Molecular Partners AG’s — who’s behind them and what they mean, delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Molecular Partners and Orano Med Strengthen Co-Development Agreement for Radio-DARPin Therapeutics
Oct 22, 2024•over 1 year ago
Contract Type
agreement
BiotechnologyTherapeuticsBiopharma
Description
Molecular Partners AG and Orano Med have strengthened their co-development agreement to include the co-development and commercialization of four Radio-DARPin programs. Each company will have the right to commercialize two of the programs, and Molecular Partners will hold commercial rights to the second nominated Radio-DARPin Candidate. The collaboration aims to develop and market Pb-based Radio-DARPin Therapeutics for the treatment of cancer.
Company Information
Company
Molecular Partners AG
About
Molecular Partners AG is a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics.
Predictive Intelligence
Strategic
ML-powered predictions for Molecular Partners AG's next move
